Screening of FDA-Approved Drugs Using a 384-Well Plate-Based Biofilm Platform: The Case of Fingolimod.

ABSTRACT: In an effort to find new repurposed antibacterial compounds, we performed the screening of an FDA-approved compounds library against Staphylococcus aureus American Type Culture Collection (ATCC) 25923. Compounds were evaluated for their capacity to prevent both planktonic growth and biofilm formation as well as to disrupt pre-formed biofilms. One of the identified initial hits was fingolimod (FTY720), an immunomodulator approved for the treatment of multiple sclerosis, which was then selected for follow-up studies. Fingolimod displayed a potent activity against S. aureus and S. epidermidis with a minimum inhibitory concentration (MIC) within the range of 12-15 µM at which concentration killing of all the bacteria was confirmed. A time-kill kinetic study revealed that fingolimod started to

SUBMITTER: Gilbert-Girard S 

PROVIDER: S-EPMC7700524 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature